Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Astellas Pharma Inc.    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Astellas Pharma : AMGEN ASTELLAS BIOPHARMA TO BECOME A WHOLLY OWNED AMGEN AFFILIATE ON APRIL 1, 2020 THE NEW COMPANY NAME WILL BE AMGEN K.K. THE HEADQUARTERS WILL RELOCATE TO TOKYO MIDTOWN

share with twitter share with LinkedIn share with facebook
share via e-mail
01/23/2020 | 01:39am EDT

Co-Promotion of Repatha®, EVENITY®, and BLINCYTO® to Continue with Astellas

Amgen Inc. (Headquarters: Thousand Oaks, California, USA; Chairman and CEO: Robert A. Bradway; 'Amgen'), Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Kenji Yasukawa, PhD., 'Astellas'), and Amgen Astellas BioPharma K.K. (Headquarters: Tokyo; President and Representative Director: Steve Sugino; 'Amgen Astellas BioPharma') announced that on April 1, 2020, Amgen will purchase the 49% of shares in Amgen Astellas BioPharma that are held by Astellas, based on the strategic alliance contract signed between Amgen and Astellas in 2013, making the company a wholly owned Amgen affiliate.

With this, Amgen Astellas BioPharma will change its name to Amgen K.K., and simultaneously relocate its Headquarters to Tokyo Midtown (9-7-1 Akasaka, Minato-ku, Tokyo). Steve Sugino will continue to serve as President and Representative Director of Amgen K.K.

Amgen Astellas BioPharma commenced business in October 2013, bringing together the strengths of Amgen, one of the world's leading independent biotechnology companies, and Astellas, a company with deep knowledge of the medical needs in Japan and a wealth of experience in the development and marketing of pharmaceutical products, as well as a strong business foundation, to contribute to healthcare in Japan through the provision of innovative medicines created by Amgen.

Since then, Amgen Astellas BioPharma and Astellas have worked together to serve patients in Japan with cardiovascular disease, cancer, and bone disease, which are three areas of significant unmet medical needs, launching Repatha® for familial hypercholesterolemia (FH) or hypercholesterolemia for patients who have high cardiovascular event risk and do not adequately respond to HMG-CoA reductase inhibitors, BLINCYTO® for patients with relapsed or refractory B-cell acute lymphoblastic leukemia, and EVENITY® for osteoporosis patients at high risk of fracture. Amgen K.K. and Astellas will continue to co-promote these three products and Astellas will remain responsible for distribution and sales of the products beyond 2020.

Amgen K.K. will carry forward Amgen's global mission to serve patients by delivering breakthrough-science-based medicines, while also striving to bring Amgen's full global pipeline of innovative medicines to patients in Japan who face unmet medical needs.

Click below for a copy of the full press release

Disclaimer

Astellas Pharma Inc. published this content on 23 January 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 January 2020 06:33:02 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTELLAS PHARMA INC.
03/30ASTELLAS PHARMA : Launches its Corporate Website's Science Section
PU
03/30ASTELLAS PHARMA INC. : Ex-dividend day for final dividend
FA
03/24CytomX Therapeutics and Astellas Announce Strategic Collaboration to Develop ..
AQ
03/23ASTELLAS PHARMA : CytomX Therapeutics and Astellas Announce Strategic Collaborat..
PU
03/18ASTELLAS PHARMA : Gifu University and Astellas establish a Research Course on Ph..
AQ
02/27ASTELLAS PHARMA : Notice Regarding the Performance-linked Stock Compensation Sch..
PU
02/20Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation fo..
AQ
02/19ASTELLAS PHARMA : and Seattle Genetics Receive FDA Breakthrough Therapy Designat..
PU
02/12ASTELLAS PHARMA : XTANDI Demonstrates Significant Improvement in Overall Surviva..
AQ
02/11SEATTLE GENETICS : and Astellas Announce Updated Results from Phase 1b/2 Trial o..
AQ
More news
Financials (JPY)
Sales 2020 1 275 B
EBIT 2020 257 B
Net income 2020 204 B
Finance 2020 458 B
Yield 2020 2,55%
P/E ratio 2020 14,2x
P/E ratio 2021 14,2x
EV / Sales2020 1,98x
EV / Sales2021 1,88x
Capitalization 2 986 B
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 2 129,17  JPY
Last Close Price 1 606,50  JPY
Spread / Highest target 80,5%
Spread / Average Target 32,5%
Spread / Lowest Target -6,63%
EPS Revisions
Managers
NameTitle
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Chikashi Takeda Senior Executive Officer & Head-Finance
Naoki Okamura Representative Director & Vice President
Tomokazu Fujisawa Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC.-1.73%28 860
JOHNSON & JOHNSON-8.82%345 705
ROCHE HOLDING AG0.02%277 060
MERCK & CO., INC-15.40%195 141
NOVARTIS-13.11%187 703
PFIZER, INC.-16.69%181 075